MacKay Geoff
Regen Med. 2006 Mar;1(2):169-74. doi: 10.2217/17460751.1.2.169.
Tissue regeneration specialist company Organogenesis Inc. was one of the first biotech companies formed. Incorporated in 1985, the company was originally a spin-off from a research program at MIT. For the first 10-15 years, Organogenesis was heavily research based, but then gradually moved into development. The company's flagship product is Apligraf--a living, bilayered skin construct with two FDA-approved indications: diabetic foot ulcers and venous leg ulcers. As Apligraf neared the market, it was necessary to 'graft' a manufacturing capability onto the company. As a consequence the company moved south from Massachusetts's cradle of biotechnology to Canton, MA, USA. Having experienced many of the highs and lows that characterize the biotech industry, the company is now consolidating its position as a center of expertise in commercializing living, cell-based products. The company has now built a sales, marketing and reimbursement team with the unique skill set to integrate novel technology into the US healthcare system. President & Chief Executive Officer Geoff MacKay takes great pride in the leading role that Organogenesis is playing in ushering in the field of tissue regeneration. Here, he discusses with Regenerative Medicine's Elisa Manzotti the 'three pillars' of the Organogenesis pipeline: bioactive wound healing, bioaesthetics and biosurgery. He focuses both on the rewards, and the trials and tribulations, of the commercialization of living cell-based technology.
组织再生专业公司奥加诺杰尼斯公司（Organogenesis Inc.）是最早成立的生物技术公司之一。该公司成立于1985年，最初是从麻省理工学院的一个研究项目中剥离出来的。在最初的10到15年里，奥加诺杰尼斯公司主要以研究为基础，但后来逐渐转向开发。该公司的旗舰产品是奥普列格夫（Apligraf）——一种具有双层结构的活性皮肤构建体，有两项获得美国食品药品监督管理局（FDA）批准的适应症：糖尿病足溃疡和下肢静脉溃疡。随着奥普列格夫接近上市，有必要为公司“嫁接”制造能力。因此，公司从马萨诸塞州的生物技术摇篮向南迁至美国马萨诸塞州的坎顿。经历了生物技术行业的诸多起起落落后，该公司现在正在巩固其作为商业化活性细胞产品专业中心的地位。该公司现已组建了一支销售、营销和报销团队，拥有将新技术整合到美国医疗保健系统中的独特技能。总裁兼首席执行官杰夫·麦凯（Geoff MacKay）对奥加诺杰尼斯公司在引领组织再生领域所发挥的主导作用深感自豪。在此，他与《再生医学》杂志的伊丽莎·曼佐蒂（Elisa Manzotti）讨论了奥加诺杰尼斯公司产品线的“三大支柱”：生物活性伤口愈合、生物美学和生物手术。他既关注基于活性细胞技术商业化的回报，也关注其中的考验与磨难。
